FDA 510(k) Database

The FDA 510(k) Premarket Notification Database is the Center for Devices and Radiological Health’s authoritative, public-facing record of 510(k) clearance decisions dating back to 1976. It consolidates essential artifacts for each cleared submission: the FDA clearance letter, the 510(k) Summary (when provided under 21 CFR 807.92), or a 510(k) Statement (when elected under 21 CFR 807.93). For regulatory teams, it is the first stop to analyze intended use, technological characteristics, and performance predicates.

In practice, the database is more than a search page. It is a living map of product codes, regulation numbers, and review panels, showing how substantial equivalence has been interpreted over time under Section 513(i) of the Federal Food, Drug, and Cosmetic Act. Used properly, it frames the boundaries of substantial equivalence, reveals special controls, and surfaces test methods that have supported clearances across a category.

Because it lists decision dates, applicants, and device names, the database also supports competitor surveillance and horizon scanning. For teams planning a submission, the entries illuminate how close comparators articulated indications for use and substantiated differences with bench, biocompatibility, software, or clinical data.

The tool does not cover PMA approvals and De Novo classifications, and it is not a substitute for device labeling or risk management records. It is best used alongside a grounded understanding of 510(k) vs PMA distinctions and an active post-market surveillance program to keep claims and safety profiles aligned as your product evolves.

The 510(k) framework is codified in 21 CFR Part 807, Subpart E. Section 807.81 defines when a premarket notification is required; 807.87 describes 510(k) content; 807.92 specifies the elements of a 510(k) Summary; 807.93 outlines the alternative 510(k) Statement; and 807.100 addresses the clearance decision. Statutorily, substantial equivalence is anchored in Section 513(i) of the FD&C Act, which sets the criteria FDA uses to compare a new device to a predicate.

The database reflects this regime. For each cleared 510(k), FDA posts the clearance letter and either the Summary or Statement. A Summary typically includes indications for use, device description, technological characteristics, performance testing, and a substantial equivalence conclusion. A Statement does not disclose details and instead affirms that supporting safety and effectiveness information may be made available to any person upon request. Sponsors choose one pathway but not both.

Scope covers most Class II and applicable Class I devices, including accessories, reviewed by CDRH or via accredited third parties. It excludes PMAs and De Novos, which have separate public listings. Redactions may be applied to protect confidential commercial information, and older records can be less standardized than recent ones as CDRH modernized templates and posting practices.

For planning, teams often read adjacent entries in a product code to understand the testing norms that underpinned recent clearances. Pair this work with strategic planning resources such as medical device development phases and jurisdictional overviews like USA medical device regulatory readiness to ensure your internal roadmap meets both premarket and lifecycle expectations.

The database supports targeted search across K-number, applicant, device name, product code, regulation number, decision date, and clinical panel. Start broad by product code or regulation number to see the landscape, then narrow by recent decision dates to align with current review expectations. Where product codes have evolved, scanning adjacent codes can reveal relevant comparators.

K-number queries are best when you already know a likely predicate. Applicant and device name searches can be noisy due to corporate name changes and branding updates. Regulation number anchoring is stable and useful for identifying special controls and test themes across a group. For horizon scanning, decision date filters and review panel filters help isolate the most recent patterns for your category.

Document what you find. Snapshot Summaries, record regulation and product codes, and capture specific test names or standards cited by recent clearances. Teams often pair this with internal dashboards to track recurring comparators and testing patterns, a workflow well-served by analytics.

Predicate selection starts with aligning intended use and indications for use, then confirming that technological characteristics do not raise different questions of safety and effectiveness. The database operationalizes this by letting you read how successful comparators framed claims and summarized testing to mitigate residual risk. Read across recent clearances within your product code to see what FDA has accepted for bench, software, electromagnetic compatibility, biocompatibility, sterilization, and clinical evidence.

Avoid forcing a fit. If your technology materially departs from the predicate family, the database will show that through divergent test regimes or explicit statements about novel performance. In those cases, early regulatory dialogue helps. Use database learnings to design your questions and evidence plan before requesting a Pre-Submission meeting.

1. Start at the regulation number to lock intended use language, then inventory recent clearances in the product code.
2. Extract indications for use and key technological characteristics from recent 510(k) Summaries.
3. List all performance tests, standards, and acceptance criteria credited in those Summaries.
4. Identify any special controls and confirm your device can meet them without new questions of safety and effectiveness.
5. Draft a comparison table showing similarities and clinically insignificant differences against your lead predicate(s).
6. Use your findings to frame focused questions for a Pre-Submission under the Q-Submission program.

As you converge on a lead predicate, triangulate with the most recent clearances to avoid relying on outdated methods. Reference definitions of a predicate device and be explicit about how you will meet contemporary expectations. For execution detail, see the 510(k) clearance readiness guide for document structure, test planning, and review choreography.

A 510(k) Summary prepared under 21 CFR 807.92 should include device description, intended use, technological characteristics, performance data, substantial equivalence rationale, and conclusions. Begin by comparing the indications for use language to your draft claims. Differences in verbs, patient population, or clinical setting matter. Next, read the technological characteristics section for attributes that drove specific testing or special controls.

Performance data sections reveal test types and, when not redacted, acceptance criteria. Note biocompatibility endpoints, shelf-life justifications, EM compatibility standards, software lifecycle evidence, and sterilization validations cited by successful comparators. When only a 510(k) Statement is present, assume core methods exist but are undisclosed and look to adjacent Summaries in the same product code to anchor your plan.

Do not confuse the clearance letter with labeling. The letter documents FDA’s decision on substantial equivalence; it does not bless every marketing claim or detail of instructions. Your final Instructions for Use (IFU) must remain aligned with cleared indications and the evidence you generated.

While authoritative, the database is not a complete technical dossier. Redactions for confidential commercial information can obscure methods or acceptance criteria, especially in older records or proprietary technologies. Company names and device titles may change over time, and product codes occasionally migrate as the taxonomy is refined. These realities can mislead a quick search.

Another frequent error is treating the database as a template generator. Summaries are sponsor-authored narratives, not FDA-authored standards. They can be uneven in depth, and silence is not endorsement. Anchor your plan to current regulations, special controls, and consensus standards where applicable, and use multiple recent comparators to triangulate norms. When in doubt, ask targeted questions through formal FDA engagement channels.

• Assuming identical indications because the device name sounds similar.
• Relying on a single, older Summary to define present-day test expectations.
• Ignoring special controls tied to the regulation number when selecting a predicate.
• Treating clearance letters as permission for unvetted marketing language.
• Missing rescissions or product code changes that reframe the landscape.
• Overlooking software or cybersecurity evidence expectations documented in newer clearances.

Mitigate by building a comparison matrix across the three most recent, highest-signal entries in your code, confirming that your language and test plan fit within Section 513(i) constraints. Document your rationale for differences and link each to evidence. Maintain alignment with evolving quality system expectations, including the FDA’s Quality Management System Regulation harmonization effort, captured in FDA QMSR.

The 510(k) database is specific to substantial equivalence determinations. PMA approvals and De Novo classifications are cataloged separately and reflect different evidentiary standards. If your device introduces new intended uses or different questions of safety and effectiveness, the predicate pathway may be inappropriate regardless of database proximity. In such cases, the public PMA or De Novo listings, not the 510(k) database, provide the relevant precedents.

Internationally, public registries vary. The European Union’s EUDAMED and national databases under the MDR and IVDR have different structures and levels of public detail. The United Kingdom, Canada, Australia, Japan, and others publish device listings or licenses with variable granularity. These are not interchangeable with 510(k) Summaries. Use jurisdiction-specific readiness resources such as EU medical device regulatory readiness and UK medical device regulatory readiness to avoid crosswalking claims or tests where frameworks diverge.

Within FDA pathways, reserve 510(k) strategies for devices that can meet Section 513(i) criteria; use PMA for Class III devices requiring reasonable assurance of safety and effectiveness, and consider De Novo for novel, low-to-moderate risk devices lacking a predicate. The comparison points in 510(k) vs PMA remain essential guardrails when interpreting database proximity as true regulatory fit.

Translate database findings into a coherent submission plan. Start with a precise problem statement and intended use that mirrors the predicate family. Draft an indications for use statement that does not broaden patient population, clinical environment, or claims. Build a comparison table that lists each relevant technological characteristic and ties differences to risk controls and evidence. For performance testing, prioritize standards and methods cited in the most recent clearances to reflect current expectations.

Integrate these choices into your risk management file and design controls. If your device includes software, document lifecycle processes and verification rigor consistent with the depth observed in recent Summaries for your code. For sterilized devices, reconcile sterilization parameters, packaging validations, and shelf-life with contemporary comparators. Align labeling and training materials to the cleared indications rather than to marketing aspirations, and preemptively plan post-market monitoring to verify real-world performance aligns with claims.

Submission choreography benefits from early, structured engagement. Where uncertainty remains, craft focused questions supported by database citations and propose a test plan, then seek FDA feedback through formal mechanisms. Internally, establish document traceability so that each claim maps to a test, each test maps to a protocol, and each protocol maps to a justified acceptance criterion derived from standards or comparator precedent.

Operationalizing 510(k) research demands rigor across document control, evidence mapping, and change management. V5 Ultimate centralizes your predicate landscape, captures the exact language and tests drawn from public records, and ties each submission claim to its validation artifacts. Teams can establish a living register of product codes and regulations, monitor competitor updates, and harden traceability between intended use, technological characteristics, risk controls, and performance data.

From first search through decision letter, V5 standardizes how your team curates Summaries, builds comparison tables, and routes protocols and reports for review. Management dashboards monitor readiness against required elements, while role-based workflows enforce sign-off for indications language, labeling, and test acceptance criteria. When the evidence plan changes, V5 keeps the submission package synchronized and audit-ready.